ES2156118T3 - Procedimiento para la deteccion y determinacion de mediadores. - Google Patents

Procedimiento para la deteccion y determinacion de mediadores.

Info

Publication number
ES2156118T3
ES2156118T3 ES93112914T ES93112914T ES2156118T3 ES 2156118 T3 ES2156118 T3 ES 2156118T3 ES 93112914 T ES93112914 T ES 93112914T ES 93112914 T ES93112914 T ES 93112914T ES 2156118 T3 ES2156118 T3 ES 2156118T3
Authority
ES
Spain
Prior art keywords
mediators
determination
detection
procedure
mediator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93112914T
Other languages
English (en)
Inventor
Karlheinz Enssle
Roland Kurrle
Klaus-Dieter Langner
Leander Lauffer
Josef-Urban Pauly
Friedrich-Robert Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2156118T3 publication Critical patent/ES2156118T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inspection Of Paper Currency And Valuable Securities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA COMPROBAR Y/O DETERMINAR MEDIADORES Y/O SUS DERIVADOS EN LIQUIDOS. CON AYUDA DE UNOS RECEPTORES SOLUBLES RECOMBINANTES DE LOS MEDIADORES A COMPROBAR SE COMPRUEBA DIRECTA O INDIRECTAMENTE EL MEDIADOR.
ES93112914T 1992-08-29 1993-08-12 Procedimiento para la deteccion y determinacion de mediadores. Expired - Lifetime ES2156118T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4228839A DE4228839A1 (de) 1992-08-29 1992-08-29 Verfahren zum Nachweis und zur Bestimmung von Mediatoren

Publications (1)

Publication Number Publication Date
ES2156118T3 true ES2156118T3 (es) 2001-06-16

Family

ID=6466759

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93112914T Expired - Lifetime ES2156118T3 (es) 1992-08-29 1993-08-12 Procedimiento para la deteccion y determinacion de mediadores.

Country Status (8)

Country Link
US (1) US6475717B1 (es)
EP (1) EP0586915B1 (es)
JP (1) JP3467058B2 (es)
AT (1) ATE200826T1 (es)
AU (1) AU680197B2 (es)
CA (1) CA2104996A1 (es)
DE (2) DE4228839A1 (es)
ES (1) ES2156118T3 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3560252B2 (ja) * 1992-08-28 2004-09-02 アベンティス ファーマ株式会社 骨関連カドヘリン様タンパク質およびその製造法
JP3472587B2 (ja) * 1992-08-28 2003-12-02 アベンティス ファーマ株式会社 骨関連カルボキシペプチダーゼ様タンパク質およびその製造法
AU3830895A (en) * 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6258944B1 (en) 1996-05-06 2001-07-10 Merck & Co., Inc. OB receptor isoforms and nucleic acids encoding them
CA2253832A1 (en) * 1996-05-06 1997-11-13 Merck & Co., Inc. Ob receptor isoforms and nucleic acids encoding them
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1079230B1 (en) * 1998-04-14 2005-08-10 Chugai Seiyaku Kabushiki Kaisha Method for screening substance promoting oligomerization of receptor protein molecules
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US7091321B2 (en) * 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
ATE368475T1 (de) * 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
CN100390282C (zh) 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
DK1572748T3 (da) 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20060216757A1 (en) * 2003-04-25 2006-09-28 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
ATE393169T1 (de) 2003-12-30 2008-05-15 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
ES2387028T3 (es) 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
JP4987484B2 (ja) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体結合が低下した抗癌抗体
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE465176T1 (de) * 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
EP1966245B1 (en) 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19 antibodies with reduced immunogenicity
CA2635618C (en) * 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
WO2012012737A2 (en) 2010-07-23 2012-01-26 The University Of Toledo Stable tregs and related materials and methods
CN113325173B (zh) * 2020-02-28 2022-02-11 深圳市亚辉龙生物科技股份有限公司 新型冠状病毒检测试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707443A (en) * 1985-04-19 1987-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same
DE3645292C2 (de) 1986-08-22 1997-12-11 Hoechst Ag Chemilumineszenzimmunoassays und ein Verfahren zu ihrer Herstellung
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
DE3844954C2 (de) 1988-02-20 1998-07-16 Hoechst Ag Spezielle chemilumineszierende Acridinderivate und ihre Verwendung in Lumineszenzimmunoassays
DE3806617A1 (de) 1988-03-02 1989-09-14 Behringwerke Ag Erzeugung hochexprimierender, rekombinanter, eukaryotischer zellen
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
DE4037837A1 (de) * 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
EP0548867A2 (en) * 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor

Also Published As

Publication number Publication date
EP0586915B1 (de) 2001-04-25
DE59310167D1 (de) 2001-05-31
US6475717B1 (en) 2002-11-05
DE4228839A1 (de) 1994-03-03
JPH06167494A (ja) 1994-06-14
JP3467058B2 (ja) 2003-11-17
AU4492493A (en) 1994-03-03
CA2104996A1 (en) 1994-03-01
ATE200826T1 (de) 2001-05-15
AU680197B2 (en) 1997-07-24
EP0586915A1 (de) 1994-03-16

Similar Documents

Publication Publication Date Title
ES2156118T3 (es) Procedimiento para la deteccion y determinacion de mediadores.
DE68902885T2 (de) Vorrichtung zum auffinden von reifenanomalien.
DE3775224D1 (de) Protonenleitergassensor und verfahren zum gasnachweis unter benutzung desselben.
DE69114020T2 (de) Bordradar zur erfassung von windscherungen.
DE3580625D1 (de) Verfahren und vorrichtung zum kontaktieren von fluessigkeiten mit feststoffen.
DE3853430T2 (de) Enzym-immunotestverfahren zum nachweis von hiv-antigenen in menschlichen seren.
DE58905700D1 (de) Verfahren zum Feststellen der erforderlichen Anstellung von Wälzlagern in Getrieben.
DE69109181T2 (de) Gel-Elektrophorese mit Fluoreszenz-Nachweisverfahren.
DE69114941T2 (de) Sensor zum Nachweis von gasförmigem Kohlendioxid.
DE3484305D1 (de) Vorrichtung zum aussenden und empfangen von lichtsignalen, insbesondere infrarotsignalen.
DE68912316T2 (de) Optischer sensor zum nachweis der eisbildung und sonstiger chemischer spezies.
DE69300439D1 (de) Erfassung von Sensor-Defekt.
ES517034A0 (es) Metodo de deteccion de grietas superficiales en piezas, particularmente en tochos.
AU1855401A (en) Screening method for candidate drugs
DE69005370D1 (de) Membranmessfühler mit Konzentration von Deformationen.
DE59104688D1 (de) Kraftsensor zur Erfassung von Kräften zwischen Bauteilen.
DE69723414D1 (de) Vorrichtung zum Ermitteln von übereinanderliegenden Blättern
DE69009752D1 (de) Differentieller verstärker mit gewinnausgleich.
DE69004527T2 (de) Verfahren zum Feststellen von Rollenstörungen in Rollenherdofensystemen.
NO913877D0 (no) Dybdemaalingsanordning med slitesterk styreinnretning.
DE69722365D1 (de) Vorrichtung zum Ermitteln von übereinanderliegenden Blättern
ES2097158T3 (es) Ensayo funcional para la determinacion de la actividad de proteina s.
NO862949D0 (no) Fremgangsmaate for detektering av defekter i metallkonstruksjoner.
DE59100065D1 (de) Kraftsensorsystem zur erfassung von zugkraeften.
DE3761400D1 (de) Messanordnung zum erfassen von kraeften und momenten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 586915

Country of ref document: ES